
HCAT Stock Forecast & Price Target
HCAT Analyst Ratings
Bulls say
Health Catalyst Inc has demonstrated increasing earnings power over the past seven years, characterized by rising EBITDA, a growing client base, and a decline in headcount, indicating efficient operations. Executive insights from hospitals suggest that volume trends are exceeding budgetary expectations, which bodes well for further revenue generation and expansion of HCAT module sales. Additionally, potential upside risk is driven by the prospect of renewed revenue growth, enhanced volumes and insurance coverage, alongside improving margins.
Bears say
Health Catalyst Inc. is experiencing a slowdown in total revenue growth, raising concerns about future revenue and EBITDA growth, particularly due to the highly penetrated total addressable market (TAM) within the healthcare sector. Despite approximately 90% of its revenue being recurring, the company has seen a decline in net dollar-based retention levels, which could threaten its long-term financial stability. Additionally, the potential failure to deliver meaningful return on investment (ROI) could lead to a significant decrease in the company's relevancy in a competitive market.
This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.
HCAT Analyst Forecast & Price Prediction
Start investing in HCAT
Order type
Buy in
Order amount
Est. shares
0 shares